Sentinel Node in Oral Cancer: The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial.

Date publication

juillet 2016

Journal

Clinical nuclear medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DOLIVET Gilles , Dr LEROUX Agnès , Dr MASTRONICOLA Romina

Tous les auteurs :
Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O'Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Junquera Gutierrez LM, Barbier L, Santamaria-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27088386

Résumé

Nuclear imaging plays a crucial role in lymphatic mapping of oral cancer. This evaluation represents a subanalysis of the original multicenter SENT trial data set, involving 434 patients with T1-T2, N0, and M0 oral squamous cell carcinoma. The impact of acquisition techniques, tracer injection timing relative to surgery, and causes of false-negative rate were assessed.

Mots clés

Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, diagnostic imaging, Female, Humans, Lymph Nodes, pathology, Lymphatic Metastasis, diagnostic imaging, Lymphoscintigraphy, methods, Male, Middle Aged, Mouth Neoplasms, diagnostic imaging, Neck, pathology, Nuclear Medicine, Radionuclide Imaging, Radiopharmaceuticals, administration & dosage, Sentinel Lymph Node, diagnostic imaging, Single Photon Emission Computed Tomography Computed Tomography, Surveys and Questionnaires

Référence

Clin Nucl Med. 2016 Jul;41(7):534-42